Alpha-mangostin Reduces Cell Viability in Sorafenib-surviving Cells by Modulating Multiple Drug Transporters in Hepg2 Hepatocellular Carcinoma Cells

Vincent Kharisma Wangsaputra, Syarinta Syarinta, Melva Louisa

Research output: Contribution to journalArticlepeer-review

Abstract

A previous study showed that alpha-mangostin (AM) showed benefit when given to sorafenib (SOR)-surviving cells. However, the mechanism was not fully understood. The present study aimed to understand the effect of AM on SOR-surviving cells and its agent concerning drug transporters. SOR-surviving cells were treated with SOR 10 μM. Surviving cells were divided into four groups of treatment, namely, vehicle only dimethyl sulfoxide (DMSO), SOR 10 μM, AM 20 μM, or combination of SOR 10 μM-AM 20 μM. As controls, HepG2 naïve cells were treated with DMSO only or AM 20 μM. Cell viability was counted using trypan blue exclusion assay. Simultaneously, the mRNA expressions of P-glycoprotein (P-gp), ABCG2, MRP2, MRP3, OCT1, and OATP1B3 drug transporters were examined with quantitative reverse transcriptase-polymerase chain reaction. Decreased mRNA expression of P-gp was found in SOR-surviving cells treated with SOR. In contrast, AM alone or SOR's combination caused a significant increase in both efflux and influx transporters, no difference in fold increase of all transporters evaluated in AM versus SOR-AM combinations. Generally, AM treatment increased the mRNA expression of all the drug transporters.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalJournal of Applied Pharmaceutical Science
Volume11
Issue number6
DOIs
Publication statusPublished - Jun 2021

Keywords

  • Alpha-mangostin
  • drug transporters
  • OCT1
  • P-glycoprotein
  • sorafenib resistance

Fingerprint

Dive into the research topics of 'Alpha-mangostin Reduces Cell Viability in Sorafenib-surviving Cells by Modulating Multiple Drug Transporters in Hepg2 Hepatocellular Carcinoma Cells'. Together they form a unique fingerprint.

Cite this